BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, Dinniwell RE, Kassam Z, Ringash J, Cummings B, Sykes J, Sherman M, Knox JJ, Dawson LA. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31:1631-1639. [PMID: 23547075 DOI: 10.1200/jco.2012.44.1659] [Cited by in Crossref: 445] [Cited by in F6Publishing: 215] [Article Influence: 49.4] [Reference Citation Analysis]
Number Citing Articles
1 Abe T, Saitoh J, Kobayashi D, Shibuya K, Koyama Y, Shimada H, Shirai K, Ohno T, Nakano T. Dosimetric comparison of carbon ion radiotherapy and stereotactic body radiotherapy with photon beams for the treatment of hepatocellular carcinoma. Radiat Oncol. 2015;10:187. [PMID: 26377092 DOI: 10.1186/s13014-015-0491-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
2 Kim TH, Park JW, Kim BH, Kim DY, Moon SH, Kim SS, Lee JH, Woo SM, Koh YH, Lee WJ, Kim CM. Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma. Oncotarget. 2017;9:4034-4043. [PMID: 29423102 DOI: 10.18632/oncotarget.23428] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
3 Gustafson MP, Bornschlegl S, Park SS, Gastineau DA, Roberts LR, Dietz AB, Hallemeier CL. Comprehensive assessment of circulating immune cell populations in response to stereotactic body radiation therapy in patients with liver cancer. Adv Radiat Oncol 2017;2:540-7. [PMID: 29204520 DOI: 10.1016/j.adro.2017.08.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
4 Chiang CL, Chan ACY, Chiu KWH, Kong FS. Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy. Front Oncol 2019;9:1157. [PMID: 31799176 DOI: 10.3389/fonc.2019.01157] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
5 Lewis AR, Padula CA, McKinney JM, Toskich BB. Ablation plus Transarterial Embolic Therapy for Hepatocellular Carcinoma Larger than 3 cm: Science, Evidence, and Future Directions. Semin Intervent Radiol 2019;36:303-9. [PMID: 31680721 DOI: 10.1055/s-0039-1697641] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
6 Habermehl D, Naumann P, Bendl R, Oelfke U, Nill S, Debus J, Combs SE. Evaluation of inter- and intrafractional motion of liver tumors using interstitial markers and implantable electromagnetic radiotransmitters in the context of image-guided radiotherapy (IGRT) - the ESMERALDA trial. Radiat Oncol 2015;10:143. [PMID: 26169281 DOI: 10.1186/s13014-015-0456-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
7 Schultheiß M, Bengsch B, Thimme R. [Hepatocellular Carcinoma]. Dtsch Med Wochenschr 2021;146:1411-20. [PMID: 34670284 DOI: 10.1055/a-1226-3047] [Reference Citation Analysis]
8 Habermehl D, Ilicic K, Dehne S, Rieken S, Orschiedt L, Brons S, Haberer T, Weber KJ, Debus J, Combs SE. The relative biological effectiveness for carbon and oxygen ion beams using the raster-scanning technique in hepatocellular carcinoma cell lines. PLoS One 2014;9:e113591. [PMID: 25460352 DOI: 10.1371/journal.pone.0113591] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
9 Wang PM, Chung NN, Hsu WC, Chang FL, Jang CJ, Scorsetti M. Stereotactic body radiation therapy in hepatocellular carcinoma: Optimal treatment strategies based on liver segmentation and functional hepatic reserve. Rep Pract Oncol Radiother 2015;20:417-24. [PMID: 26696781 DOI: 10.1016/j.rpor.2015.03.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
10 Dionisi F, Guarneri A, Dell'Acqua V, Leonardi M, Niespolo R, Macchia G, Comito T, Amichetti M, Franco P, Cilla S, Caravatta L, Alongi F, Mantello G. Radiotherapy in the multidisciplinary treatment of liver cancer: a survey on behalf of the Italian Association of Radiation Oncology. Radiol Med 2016;121:735-43. [PMID: 27255503 DOI: 10.1007/s11547-016-0650-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
11 Laine AM, Pompos A, Timmerman R, Jiang S, Story MD, Pistenmaa D, Choy H. The Role of Hypofractionated Radiation Therapy with Photons, Protons, and Heavy Ions for Treating Extracranial Lesions. Front Oncol 2015;5:302. [PMID: 26793619 DOI: 10.3389/fonc.2015.00302] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
12 Venkat PS, Hoffe SE, Frakes JM. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control 2017;24:1073274817729259. [PMID: 28975831 DOI: 10.1177/1073274817729259] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
13 Hsu CY, Wang CW, Cheng AL, Kuo SH. Hypofractionated particle beam therapy for hepatocellular carcinoma–a brief review of clinical effectiveness. World J Gastrointest Oncol 2019; 11(8): 579-588 [PMID: 31435460 DOI: 10.4251/wjgo.v11.i8.579] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
14 Lee S, Jung J, Park JH, Kim SY, Choi J, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, Park HH, Kim JH, Yoon SM. Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients. BMC Cancer 2022;22:175. [PMID: 35172769 DOI: 10.1186/s12885-022-09263-3] [Reference Citation Analysis]
15 Gkika E, Schultheiss M, Bettinger D, Maruschke L, Neeff HP, Schulenburg M, Adebahr S, Kirste S, Nestle U, Thimme R, Grosu AL, Brunner TB. Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma. Radiat Oncol 2017;12:116. [PMID: 28701219 DOI: 10.1186/s13014-017-0851-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
16 Haridass A. Developments in Stereotactic Body Radiotherapy. Cancers (Basel) 2018;10:E497. [PMID: 30544488 DOI: 10.3390/cancers10120497] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
17 Choi SH, Seong J. Stereotactic Body Radiotherapy: Does It Have a Role in Management of Hepatocellular Carcinoma? Yonsei Med J. 2018;59:912-922. [PMID: 30187697 DOI: 10.3349/ymj.2018.59.8.912] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
18 Chiang CL, Chan MKH, Yeung CSY, Ho CHM, Lee FAS, Lee VWY, Wong FCS, Blanck O. Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B-C hepatocellular carcinoma. Strahlenther Onkol 2019;195:254-64. [PMID: 30413833 DOI: 10.1007/s00066-018-1391-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
19 O'Sullivan S, Cagney DN. The emerging role of stereotactic radiotherapy in gastrointestinal malignancies: a review of the literature and analysis from the Irish perspective. Ir J Med Sci 2018;187:887-94. [PMID: 29423821 DOI: 10.1007/s11845-018-1755-8] [Reference Citation Analysis]
20 Bang A, Dawson LA. Radiotherapy for HCC: Ready for prime time? JHEP Rep 2019;1:131-7. [PMID: 32039361 DOI: 10.1016/j.jhepr.2019.05.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
21 Dreher C, Oechsner M, Mayinger M, Beierl S, Duma MN, Combs SE, Habermehl D. Evaluation of the tumor movement and the reproducibility of two different immobilization setups for image-guided stereotactic body radiotherapy of liver tumors. Radiat Oncol 2018;13:15. [PMID: 29378624 DOI: 10.1186/s13014-018-0962-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Kreidieh M, Zeidan YH, Shamseddine A. The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary Liver Tumors. J Oncol. 2019;2019:4304817. [PMID: 31182960 DOI: 10.1155/2019/4304817] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
23 Lewis S, Dawson L, Barry A, Stanescu T, Mohamad I, Hosni A. Stereotactic body radiation therapy for hepatocellular carcinoma: from infancy to ongoing maturity. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100498] [Reference Citation Analysis]
24 Shampain KL, Hackett CE, Towfighi S, Aslam A, Masch WR, Harris AC, Chang SD, Khanna K, Mendiratta V, Gabr AM, Owen D, Mendiratta-Lala M. SBRT for HCC: Overview of technique and treatment response assessment. Abdom Radiol (NY) 2021;46:3615-24. [PMID: 33963419 DOI: 10.1007/s00261-021-03107-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. J Hepatol 2017;67:173-83. [PMID: 28323121 DOI: 10.1016/j.jhep.2017.03.007] [Cited by in Crossref: 90] [Cited by in F6Publishing: 100] [Article Influence: 18.0] [Reference Citation Analysis]
26 Lischalk JW, Repka MC, Unger K. Radiation therapy for hepatobiliary malignancies. J Gastrointest Oncol. 2017;8:279-292. [PMID: 28480067 DOI: 10.21037/jgo.2016.08.02] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
27 Sharma H. Role of external beam radiation therapy in management of hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S122-S125. [PMID: 25755603 DOI: 10.1016/j.jceh.2014.05.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
28 Feng M, Suresh K, Schipper MJ, Bazzi L, Ben-Josef E, Matuszak MM, Parikh ND, Welling TH, Normolle D, Ten Haken RK, Lawrence TS. Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial. JAMA Oncol 2018;4:40-7. [PMID: 28796864 DOI: 10.1001/jamaoncol.2017.2303] [Cited by in Crossref: 70] [Cited by in F6Publishing: 61] [Article Influence: 23.3] [Reference Citation Analysis]
29 Su TS, Lu HZ, Cheng T, Zhou Y, Huang Y, Gao YC, Tang MY, Jiang HY, Lian ZP, Hou EC, Liang P. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm. BMC Cancer 2016;16:834. [PMID: 27809890 DOI: 10.1186/s12885-016-2894-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
30 Dutta D, Tatineni T, Yarlagadda S, Gupte A, Reddy SK, Madhavan R, Nair H, Sasidharan A, Kannan R, Pottayil SG, Holla R, Sudhindran S. Hepatocellular carcinoma patients with portal vein thrombosis treated with robotic radiosurgery: Interim results of a prospective study. Indian J Gastroenterol 2021;40:389-401. [PMID: 34694581 DOI: 10.1007/s12664-021-01172-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Scher N, Janoray G, Riet FG, Le Bayon AG, Debbi K, Lévy S, Louisot P, Garaud P, Chajon E, Barillot I, Salamé É, de Crevoisier R, Chapet S, Calais G. [Stereotactic body radiation therapy for hepatocellular carcinoma: Results from a retrospective multicentre study]. Cancer Radiother 2019;23:104-15. [PMID: 30952560 DOI: 10.1016/j.canrad.2018.07.138] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Chiang CL, Chiu KW, Lee FA, Kong FS, Chan AC. Combined Stereotactic Body Radiotherapy and Immunotherapy Versus Transarterial Chemoembolization in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Front Oncol 2021;11:798832. [PMID: 34950594 DOI: 10.3389/fonc.2021.798832] [Reference Citation Analysis]
33 Marrero J, Maluccio MA, McCurdy H, Abou-Alfa GK. Expert perspectives on evidence-based treatment planning for patients with hepatocellular carcinoma. Cancer Control 2014;21:5-16. [PMID: 24681845 DOI: 10.1177/1073274814021002s02] [Reference Citation Analysis]
34 Yamashita H, Onishi H, Murakami N, Matsumoto Y, Matsuo Y, Nomiya T, Nakagawa K. Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma. J Radiat Res. 2015;56:561-567. [PMID: 25691453 DOI: 10.1093/jrr/rru130] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 5.9] [Reference Citation Analysis]
35 Kavanagh BD. Stereotactic body radiation therapy as a derivative of stereotactic radiosurgery: clinically independent but with enduring common themes. J Clin Oncol 2014;32:2827-31. [PMID: 25113758 DOI: 10.1200/JCO.2014.56.7362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
36 Park J, Park JW, Kang MK. Current status of stereotactic body radiotherapy for the treatment of hepatocellular carcinoma. Yeungnam Univ J Med 2019;36:192-200. [PMID: 31620633 DOI: 10.12701/yujm.2019.00269] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Qiu H, Moravan MJ, Milano MT, Usuki KY, Katz AW. SBRT for Hepatocellular Carcinoma: 8-Year Experience from a Regional Transplant Center. J Gastrointest Cancer 2018;49:463-9. [PMID: 28710606 DOI: 10.1007/s12029-017-9990-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
38 Hong TS, Bosch WR, Krishnan S, Kim TK, Mamon HJ, Shyn P, Ben-Josef E, Seong J, Haddock MG, Cheng JC, Feng MU, Stephans KL, Roberge D, Crane C, Dawson LA. Interobserver variability in target definition for hepatocellular carcinoma with and without portal vein thrombus: radiation therapy oncology group consensus guidelines. Int J Radiat Oncol Biol Phys 2014;89:804-13. [PMID: 24969794 DOI: 10.1016/j.ijrobp.2014.03.041] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
39 Chadha AS, Gunther JR, Hsieh CE, Aliru M, Mahadevan LS, Venkatesulu BP, Crane CH, Das P, Herman JM, Koay EJ, Taniguchi C, Holliday EB, Minsky BD, Suh Y, Park P, Sawakuchi G, Beddar S, Odisio BC, Gupta S, Loyer E, Kaur H, Raghav K, Javle MM, Kaseb AO, Krishnan S. Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. Radiother Oncol 2019;133:54-61. [PMID: 30935582 DOI: 10.1016/j.radonc.2018.10.041] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
40 Bretschneider T, Ricke J, Gebauer B, Streitparth F. Image-guided high-dose-rate brachytherapy of malignancies in various inner organs - technique, indications, and perspectives. J Contemp Brachytherapy 2016;8:251-61. [PMID: 27504135 DOI: 10.5114/jcb.2016.61068] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
41 Kim TH, Park JW, Kim YJ, Kim BH, Woo SM, Moon SH, Kim SS, Lee WJ, Kim DY, Kim CM. Simultaneous integrated boost-intensity modulated radiation therapy for inoperable hepatocellular carcinoma. Strahlenther Onkol 2014;190:882-90. [PMID: 24638270 DOI: 10.1007/s00066-014-0643-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
42 Liu Y, Li J, Cheng X, Zhang X. Bibliometric Analysis of the Top-Cited Publications and Research Trends for Stereotactic Body Radiotherapy. Front Oncol 2021;11:795568. [PMID: 34926312 DOI: 10.3389/fonc.2021.795568] [Reference Citation Analysis]
43 Lee S, Kim H, Ji Y, Cho B, Kim SS, Jung J, Kwak J, Park JH, Lee SW, Kim JH, Yoon SM. Evaluation of Hepatic Toxicity after Repeated Stereotactic Body Radiation Therapy for Recurrent Hepatocellular Carcinoma using Deformable Image Registration. Sci Rep 2018;8:16224. [PMID: 30385839 DOI: 10.1038/s41598-018-34676-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
44 Wang PM, Hsu WC, Chung NN, Chang FL, Jang CJ, Fogliata A, Scorsetti M, Cozzi L. Feasibility of stereotactic body radiation therapy with volumetric modulated arc therapy and high intensity photon beams for hepatocellular carcinoma patients. Radiat Oncol 2014;9:18. [PMID: 24410988 DOI: 10.1186/1748-717X-9-18] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 2.9] [Reference Citation Analysis]
45 Ibragimov B, Toesca D, Chang D, Yuan Y, Koong A, Xing L. Development of deep neural network for individualized hepatobiliary toxicity prediction after liver SBRT. Med Phys. 2018;45:4763-4774. [PMID: 30098025 DOI: 10.1002/mp.13122] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 12.0] [Reference Citation Analysis]
46 Tsurugai Y, Takeda A, Sanuki N, Eriguchi T, Ueno M. Three Cases of Hepatocellular Carcinoma With Massive Macrovascular Invasion Successfully Treated With Radiotherapy. Cureus 2021;13:e18624. [PMID: 34765376 DOI: 10.7759/cureus.18624] [Reference Citation Analysis]
47 Bennett S, Søreide K, Gholami S, Pessaux P, Teh C, Segelov E, Kennecke H, Prenen H, Myrehaug S, Callegaro D, Hallet J. Strategies for the delay of surgery in the management of resectable hepatobiliary malignancies during the COVID-19 pandemic. Curr Oncol 2020;27:e501-11. [PMID: 33173390 DOI: 10.3747/co.27.6785] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
48 Mo H, Zhong J. Comment on stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma. J Surg Oncol 2016;113:715-715. [DOI: 10.1002/jso.24192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
49 Ng SSW, Zhang H, Wang L, Citrin D, Dawson LA. Association of pro-inflammatory soluble cytokine receptors early during hepatocellular carcinoma stereotactic radiotherapy with liver toxicity. NPJ Precis Oncol 2020;4:17. [PMID: 32695883 DOI: 10.1038/s41698-020-0124-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 McCulloch MM, Muenz DG, Schipper MJ, Velec M, Dawson LA, Brock KK. A simulation study to assess the potential impact of developing normal tissue complication probability models with accumulated dose. Adv Radiat Oncol 2018;3:662-72. [PMID: 30370368 DOI: 10.1016/j.adro.2018.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
51 Le Bon M, Lapeyre M, Moreau J, Bellière-Calandry A, Pezet D, Abergel A, Bellini R, Kwiatkowski F, Verrelle P, Martin F, Benoît C. [Tolerance of hypofractionated stereotactic radiotherapy for hepatic tumours]. Cancer Radiother 2019;23:385-94. [PMID: 31300328 DOI: 10.1016/j.canrad.2019.02.004] [Reference Citation Analysis]
52 Bossé D, Ng T, Ahmad C, Alfakeeh A, Alruzug I, Biagi J, Brierley J, Chaudhury P, Cleary S, Colwell B, Cripps C, Dawson LA, Dorreen M, Ferland E, Galiatsatos P, Girard S, Gray S, Halwani F, Kopek N, Mahmud A, Martel G, Robillard L, Samson B, Seal M, Siddiqui J, Sideris L, Snow S, Thirwell M, Vickers M, Goodwin R, Goel R, Hsu T, Tsvetkova E, Ward B, Asmis T. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. Curr Oncol 2016;23:e605-14. [PMID: 28050151 DOI: 10.3747/co.23.3394] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
53 Zhang-velten E, Sanford NN. The Evolving Role of Hypofractionated Radiotherapy in Older Adults with Gastrointestinal Cancers. Seminars in Radiation Oncology 2022;32:159-67. [DOI: 10.1016/j.semradonc.2021.11.005] [Reference Citation Analysis]
54 Lurje I, Werner W, Mohr R, Roderburg C, Tacke F, Hammerich L. In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. Front Immunol 2021;12:650486. [PMID: 34025657 DOI: 10.3389/fimmu.2021.650486] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Kim TH, Park JW, Kim BH, Kim H, Moon SH, Kim SS, Woo SM, Koh YH, Lee WJ, Kim DY, Kim CM. Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma? Cancers (Basel). 2019;11. [PMID: 30781391 DOI: 10.3390/cancers11020230] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
56 Mullikin TC, Pepin KM, Evans JE, Venkatesh SK, Ehman RL, Merrell KW, Haddock MG, Harmsen WS, Herman MG, Hallemeier CL. Evaluation of Pretreatment Magnetic Resonance Elastography for the Prediction of Radiation-Induced Liver Disease. Adv Radiat Oncol 2021;6:100793. [PMID: 34820550 DOI: 10.1016/j.adro.2021.100793] [Reference Citation Analysis]
57 Mendiratta-Lala M, Masch W, Shankar PR, Hartman HE, Davenport MS, Schipper MJ, Maurino C, Cuneo KC, Lawrence TS, Owen D. Magnetic Resonance Imaging Evaluation of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy: Long Term Imaging Follow-Up. Int J Radiat Oncol Biol Phys 2019;103:169-79. [PMID: 30213751 DOI: 10.1016/j.ijrobp.2018.09.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
58 Scorsetti M, Comito T, Cozzi L, Clerici E, Tozzi A, Franzese C, Navarria P, Fogliata A, Tomatis S, D'Agostino G, Iftode C, Mancosu P, Ceriani R, Torzilli G. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol. 2015;141:1301-1309. [PMID: 25644863 DOI: 10.1007/s00432-015-1929-y] [Cited by in Crossref: 93] [Cited by in F6Publishing: 78] [Article Influence: 13.3] [Reference Citation Analysis]
59 Isaac EI, Hall J, Dault JB, Elbich J, Mcghee A, Fields EC. Transarterial Chemoembolization with LC Bead LUMI followed by Stereotactic Body Radiation Therapy in Treatment of Hepatocellular Carcinoma. Advances in Radiation Oncology 2022;7:100830. [DOI: 10.1016/j.adro.2021.100830] [Reference Citation Analysis]
60 Gottumukkala S, Tumati V, Hrycushko B, Folkert M. Endoluminal and Interstitial Brachytherapy for the Treatment of Gastrointestinal Malignancies: a Systematic Review. Curr Oncol Rep. 2017;19:2. [PMID: 28110462 DOI: 10.1007/s11912-017-0561-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
61 Jin Q, Hu H, Yan S, Jin L, Pan Y, Li X, Peng Y, Cao P. lncRNA MIR22HG-Derived miR-22-5p Enhances the Radiosensitivity of Hepatocellular Carcinoma by Increasing Histone Acetylation Through the Inhibition of HDAC2 Activity. Front Oncol 2021;11:572585. [PMID: 33718133 DOI: 10.3389/fonc.2021.572585] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
62 Ng SSW, Jang GH, Kurland IJ, Qiu Y, Guha C, Dawson LA. Plasma metabolomic profiles in liver cancer patients following stereotactic body radiotherapy. EBioMedicine. 2020;59:102973. [PMID: 32891936 DOI: 10.1016/j.ebiom.2020.102973] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
63 Leung HWC, Chan ALF. Cost-utility of stereotactic radiation therapy versus proton beam therapy for inoperable advanced hepatocellular carcinoma. Oncotarget. 2017;8:75568-75576. [PMID: 29088891 DOI: 10.18632/oncotarget.17369] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
64 Siddiqui O, Pollock A, Samanta S, Kaiser A, Molitoris JK. Proton Beam Therapy in Liver Malignancies. Curr Oncol Rep 2020;22:30. [PMID: 32108284 DOI: 10.1007/s11912-020-0889-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Pollom EL, Lee K, Durkee BY, Grade M, Mokhtari DA, Wahl DR, Feng M, Kothary N, Koong AC, Owens DK, Goldhaber-Fiebert J, Chang DT. Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study. Radiology 2017;283:460-8. [PMID: 28045603 DOI: 10.1148/radiol.2016161509] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
66 Chok KS. Management of recurrent hepatocellular carcinoma after liver transplant. World J Hepatol 2015; 7(8): 1142-1148 [PMID: 26052403 DOI: 10.4254/wjh.v7.i8.1142] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
67 Takeda A, Sanuki N, Kunieda E. Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer. World J Gastroenterol 2014; 20(15): 4220-4229 [PMID: 24764660 DOI: 10.3748/wjg.v20.i15.4220] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
68 Ohri N, Dawson LA, Krishnan S, Seong J, Cheng JC, Sarin SK, Kinkhabwala M, Ahmed MM, Vikram B, Coleman CN, Guha C. Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. J Natl Cancer Inst. 2016;108. [PMID: 27377923 DOI: 10.1093/jnci/djw133] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
69 Yang JF, Lo CH, Lee MS, Lin CS, Dai YH, Shen PC, Chao HL, Huang WY. Stereotactic ablative radiotherapy versus conventionally fractionated radiotherapy in the treatment of hepatocellular carcinoma with portal vein invasion: a retrospective analysis. Radiat Oncol 2019;14:180. [PMID: 31640728 DOI: 10.1186/s13014-019-1382-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
70 Bettinger D, Pinato DJ, Schultheiss M, Sharma R, Rimassa L, Pressiani T, Burlone ME, Pirisi M, Kudo M, Park JW, Buettner N, Neumann-Haefelin C, Boettler T, Abbasi-Senger N, Alheit H, Baus W, Blanck O, Gerum S, Guckenberger M, Habermehl D, Ostheimer C, Riesterer O, Tamihardja J, Grosu AL, Thimme R, Brunner TB, Gkika E. Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis. Liver Cancer 2019;8:281-94. [PMID: 31602371 DOI: 10.1159/000490260] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
71 Li D, Kang J, Golas BJ, Yeung VW, Madoff DC. Minimally invasive local therapies for liver cancer. Cancer Biol Med. 2014;11:217-236. [PMID: 25610708 DOI: 10.7497/j.issn.2095-3941.2014.04.001] [Cited by in F6Publishing: 25] [Reference Citation Analysis]
72 Hong TS, Grassberger C, Yeap BY, Jiang W, Wo JY, Goyal L, Clark JW, Crane CH, Koay EJ, Dima S, Eyler CE, Popescu I, DeLaney TF, Zhu AX, Duda DG. Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy. NPJ Precis Oncol 2018;2:22. [PMID: 30374460 DOI: 10.1038/s41698-018-0065-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
73 Que J, Kuo HT, Lin LC, Lin KL, Lin CH, Lin YW, Yang CC. Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma. BMC Cancer 2016;16:451. [PMID: 27405814 DOI: 10.1186/s12885-016-2512-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
74 Poon RT, Cheung TT, Kwok PC, Lee AS, Li TW, Loke KL, Chan SL, Cheung MT, Lai TW, Cheung CC. Hong Kong consensus recommendations on the management of hepatocellular carcinoma. Liver Cancer. 2015;4:51-69. [PMID: 26020029 DOI: 10.1159/000367728] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
75 Song JH, Son SH, Kay CS, Jang HS. Reducing the probability of radiation-induced hepatic toxicity by changing the treatment modality from helical tomotherapy to fixed-beam intensity-modulated radiotherapy. Oncotarget. 2015;6:33952-33960. [PMID: 26376679 DOI: 10.18632/oncotarget.5581] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
76 Robbins JR, Schmid RK, Hammad AY, Gamblin TC, Erickson BA. Stereotactic body radiation therapy for hepatocellular carcinoma: Practice patterns, dose selection and factors impacting survival. Cancer Med 2019;8:928-38. [PMID: 30701703 DOI: 10.1002/cam4.1948] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
77 Byrne TJ, Rakela J. Loco-regional therapies for patients with hepatocellular carcinoma awaiting liver transplantation: Selecting an optimal therapy. World J Transplant 2016; 6(2): 306-313 [PMID: 27358775 DOI: 10.5500/wjt.v6.i2.306] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
78 Hasan S, Thai N, Uemura T, Kudithipudi V, Renz P, Abel S, Kirichenko AV. Hepatocellular carcinoma with child Pugh-A Cirrhosis treated with stereotactic body radiotherapy. World J Gastrointest Surg 2017; 9(12): 256-263 [PMID: 29359031 DOI: 10.4240/wjgs.v9.i12.256] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
79 Lee YH, Tai D, Yip C, Choo SP, Chew V. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond. Front Immunol 2020;11:568759. [PMID: 33117354 DOI: 10.3389/fimmu.2020.568759] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
80 Schoenberg M, Khandoga A, Stintzing S, Trumm C, Schiergens TS, Angele M, Op den Winkel M, Werner J, Muacevic A, Rentsch M. CyberKnife Radiosurgery - Value as an Adjunct to Surgical Treatment of HCC? Cureus 2016;8:e591. [PMID: 27284498 DOI: 10.7759/cureus.591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
81 Yoon SM, Kim SY, Lim YS, Kim KM, Shim JH, Lee D, An J, Jung J, Kim JH, Lee HC. Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial. Clin Mol Hepatol 2020;26:506-15. [PMID: 32646200 DOI: 10.3350/cmh.2020.0038] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
82 Lin TA, Lin JS, Wagner T, Pham N. Stereotactic body radiation therapy in primary hepatocellular carcinoma: current status and future directions. J Gastrointest Oncol 2018;9:858-70. [PMID: 30505586 DOI: 10.21037/jgo.2018.06.01] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
83 Likhitsup A, Razumilava N, Parikh ND. Treatment for Advanced Hepatocellular Carcinoma: Current Standard and the Future. Clin Liver Dis (Hoboken) 2019;13:13-9. [PMID: 31168360 DOI: 10.1002/cld.782] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
84 Lo CH, Yang JF, Liu MY, Jen YM, Lin CS, Chao HL, Huang WY. Survival and prognostic factors for patients with advanced hepatocellular carcinoma after stereotactic ablative radiotherapy. PLoS One 2017;12:e0177793. [PMID: 28545098 DOI: 10.1371/journal.pone.0177793] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
85 Seo YS, Kim MS, Yoo HJ, Jang WI, Paik EK, Han CJ, Lee BH. Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a Markov model-based analysis. Cancer Med 2016;5:3094-101. [PMID: 27709795 DOI: 10.1002/cam4.893] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
86 Vainshtein JM, Kabarriti R, Mehta KJ, Roy-Chowdhury J, Guha C. Bone marrow-derived stromal cell therapy in cirrhosis: clinical evidence, cellular mechanisms, and implications for the treatment of hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2014;89:786-803. [PMID: 24969793 DOI: 10.1016/j.ijrobp.2014.02.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
87 Roberts HJ, Wo JY. Stereotactic body radiation therapy for primary liver tumors: An effective liver-directed therapy in the toolbox. Cancer 2021. [PMID: 34847255 DOI: 10.1002/cncr.34033] [Reference Citation Analysis]
88 Hong TS, DeLaney TF, Mamon HJ, Willett CG, Yeap BY, Niemierko A, Wolfgang JA, Lu HM, Adams J, Weyman EA. A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors. Pract Radiat Oncol. 2014;4:316-322. [PMID: 25194100 DOI: 10.1016/j.prro.2013.10.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
89 Gerum S, Heinz C, Belka C, Walter F, Paprottka P, De Toni EN, Roeder F. Stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma and oligometastatic liver disease. Radiat Oncol. 2018;13:100. [PMID: 29843752 DOI: 10.1186/s13014-018-1048-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
90 Moore A, Cohen-Naftaly M, Benjaminov O, Braun M, Issachar A, Mor E, Tovar A, Sarfaty M, Gordon N, Stemmer SM. Radiotherapy and Sorafenib in the Management of Patients with Hepatocellular Carcinoma Have Led to Improved Survival: A Single Center Experience. J Cancer 2016;7:883-9. [PMID: 27313777 DOI: 10.7150/jca.14721] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
91 Parzen JS, Hartsell W, Chang J, Apisarnthanarax S, Molitoris J, Durci M, Tsai H, Urbanic J, Ashman J, Vargas C, Stevens C, Kabolizadeh P. Hypofractionated proton beam radiotherapy in patients with unresectable liver tumors: multi-institutional prospective results from the Proton Collaborative Group. Radiat Oncol 2020;15:255. [PMID: 33148296 DOI: 10.1186/s13014-020-01703-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Chung H, Jung J, Jeong C, Kwak J, Park JH, Kim SS, Yoon SM, Song SY, Kim JH, Choi EK, Cho S, Cho B. Evaluation of delivered dose to a moving target by 4D dose reconstruction in gated volumetric modulated arc therapy. PLoS One 2018;13:e0202765. [PMID: 30192793 DOI: 10.1371/journal.pone.0202765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
93 Apisarnthanarax S, Barry A, Cao M, Czito B, DeMatteo R, Drinane M, Hallemeier CL, Koay EJ, Lasley F, Meyer J, Owen D, Pursley J, Schaub SK, Smith G, Venepalli NK, Zibari G, Cardenes H. External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol 2021:S1879-8500(21)00233-2. [PMID: 34688956 DOI: 10.1016/j.prro.2021.09.004] [Reference Citation Analysis]
94 Kimura T, Aikata H, Doi Y, Imano N, Takeuchi Y, Takahashi I, Nishibuchi I, Katsuta T, Kenjo M, Murakami Y, Awai K, Chayama K, Nagata Y. Comparison of Stereotactic Body Radiation Therapy Combined With or Without Transcatheter Arterial Chemoembolization for Patients With Small Hepatocellular Carcinoma Ineligible for Resection or Ablation Therapies. Technol Cancer Res Treat. 2018;17:1533033818783450. [PMID: 29963972 DOI: 10.1177/1533033818783450] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
95 Jang WI, Kim MS, Bae SH, Cho CK, Yoo HJ, Seo YS, Kang JK, Kim SY, Lee DH, Han CJ. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat Oncol. 2013;8:250. [PMID: 24160944 DOI: 10.1186/1748-717x-8-250] [Cited by in Crossref: 124] [Cited by in F6Publishing: 56] [Article Influence: 13.8] [Reference Citation Analysis]
96 Keane FK, Wo JY, Zhu AX, Hong TS. Liver-Directed Radiotherapy for Hepatocellular Carcinoma. Liver Cancer 2016;5:198-209. [PMID: 27493895 DOI: 10.1159/000367764] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
97 Chopra S, George K, Engineer R, Rajamanickam K, Nojin S, Joshi K, Swamidas J, Shetty N, Patkar S, Patil P, Ostwal V, Mehta S, Goel M. Stereotactic body radio therapy for inoperable large hepatocellular cancers: results from a clinical audit. Br J Radiol 2019;92:20181053. [PMID: 31219706 DOI: 10.1259/bjr.20181053] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
98 Petrowsky H, Fritsch R, Guckenberger M, De Oliveira ML, Dutkowski P, Clavien P. Modern therapeutic approaches for the treatment of malignant liver tumours. Nat Rev Gastroenterol Hepatol 2020;17:755-72. [DOI: 10.1038/s41575-020-0314-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 11.5] [Reference Citation Analysis]
99 Pérez-Romasanta LA, González-Del Portillo E, Rodríguez-Gutiérrez A, Matías-Pérez Á. Stereotactic Radiotherapy for Hepatocellular Carcinoma, Radiosensitization Strategies and Radiation-Immunotherapy Combination. Cancers (Basel) 2021;13:E192. [PMID: 33430362 DOI: 10.3390/cancers13020192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
100 Kong VC, Velec M. Stereotactic Body Radiation Therapy for Liver Cancer: A Review of the Technology. J Med Imaging Radiat Sci 2015;46:343-50. [PMID: 31052142 DOI: 10.1016/j.jmir.2015.06.005] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
101 Hasan S, Abel S, Verma V, Webster P, Arscott WT, Wegner RE, Kirichenko A, Simone CB 2nd. Proton beam therapy versus stereotactic body radiotherapy for hepatocellular carcinoma: practice patterns, outcomes, and the effect of biologically effective dose escalation. J Gastrointest Oncol 2019;10:999-1009. [PMID: 31602338 DOI: 10.21037/jgo.2019.08.03] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
102 Gkika E, Bettinger D, Krafft L, Schultheiss M, Neeff HP, Maruschke L, Schulenburg M, Adebahr S, Kirste S, Nestle U, Thimme R, Grosu A, Brunner TB. The role of albumin–bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy. Strahlenther Onkol 2018;194:403-13. [DOI: 10.1007/s00066-017-1256-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
103 Byun HK, Kim HJ, Im YR, Kim DY, Han K, Seong J. Dose escalation in radiotherapy for incomplete transarterial chemoembolization of hepatocellular carcinoma. Strahlenther Onkol 2020;196:132-41. [DOI: 10.1007/s00066-019-01488-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
104 Leung HW, Liu CF, Chan AL. Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma. Radiat Oncol. 2016;11:69. [PMID: 27193904 DOI: 10.1186/s13014-016-0644-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
105 Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, Han G, Wang M, Liu R, Lu L, Ren Z, Chen M, Zeng Z, Liang P, Liang C, Chen M, Yan F, Wang W, Ji Y, Yun J, Cai D, Chen Y, Cheng W, Cheng S, Dai C, Guo W, Hua B, Huang X, Jia W, Li Y, Li Y, Liang J, Liu T, Lv G, Mao Y, Peng T, Ren W, Shi H, Shi G, Tao K, Wang W, Wang X, Wang Z, Xiang B, Xing B, Xu J, Yang J, Yang J, Yang Y, Yang Y, Ye S, Yin Z, Zhang B, Zhang B, Zhang L, Zhang S, Zhang T, Zhao Y, Zheng H, Zhu J, Zhu K, Liu R, Shi Y, Xiao Y, Dai Z, Teng G, Cai J, Wang W, Cai X, Li Q, Shen F, Qin S, Dong J, Fan J. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer 2020;9:682-720. [PMID: 33442540 DOI: 10.1159/000509424] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
106 Herrmann E, Naehrig D, Sassowsky M, Bigler M, Buijsen J, Ciernik I, Zwahlen D, Pellanda AF, Meister A, Brauchli P, Berardi S, Kuettel E, Dufour JF, Aebersold DM; Swiss Group for Clinical Cancer Research (SAKK). External beam radiotherapy for unresectable hepatocellular carcinoma, an international multicenter phase I trial, SAKK 77/07 and SASL 26. Radiat Oncol 2017;12:12. [PMID: 28086942 DOI: 10.1186/s13014-016-0745-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
107 Liao J, Jin H, Li S, Xu L, Peng Z, Wei G, Long J, Guo Y, Kuang M, Zhou Q, Peng S. Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res 2019;38:454. [PMID: 31694662 DOI: 10.1186/s13046-019-1419-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
108 Pollom EL, Feng M, Chang DT. Comparing Modalities Using the National Cancer Database: Concerns With Rajyaguru et al. J Clin Oncol 2018;36:2557. [PMID: 29945518 DOI: 10.1200/JCO.2018.78.0403] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
109 El Naqa I, Johansson A, Owen D, Cuneo K, Cao Y, Matuszak M, Bazzi L, Lawrence TS, Ten Haken RK. Modeling of Normal Tissue Complications Using Imaging and Biomarkers After Radiation Therapy for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2018;100:335-43. [PMID: 29353652 DOI: 10.1016/j.ijrobp.2017.10.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
110 Costentin CE, Ferrone CR, Arellano RS, Ganguli S, Hong TS, Zhu AX. Hepatocellular Carcinoma with Macrovascular Invasion: Defining the Optimal Treatment Strategy. Liver Cancer 2017;6:360-74. [PMID: 29234639 DOI: 10.1159/000481315] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
111 Llacer-Moscardo C, Riou O, Azria D, Bedos L, Ailleres N, Quenet F, Rouanet P, Ychou M, Fenoglietto P. Imaged-guided liver stereotactic body radiotherapy using VMAT and real-time adaptive tumor gating. Concerns about technique and preliminary clinical results. Rep Pract Oncol Radiother 2017;22:141-9. [PMID: 28490985 DOI: 10.1016/j.rpor.2016.06.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
112 Yu JI, Park HC, Lim DH, Paik SW. Do Biliary Complications after Hypofractionated Radiation Therapy in Hepatocellular Carcinoma Matter? Cancer Res Treat. 2016;48:574-582. [PMID: 26194367 DOI: 10.4143/crt.2015.076] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
113 Beaton L, Daly M, Tregidgo HF, Grimes H, Moinuddin S, Stacey C, Znati S, Hague J, Bascal ZA, Wilde PE, Cooper S, Bandula S, Lewis AL, Clarkson MJ, Sharma RA. Radiopaque drug-eluting embolisation beads as fiducial markers for stereotactic liver radiotherapy. Br J Radiol 2021;:20210594. [PMID: 34762499 DOI: 10.1259/bjr.20210594] [Reference Citation Analysis]
114 Mohan V, Bruin NM, van de Kamer JB, Sonke JJ, Vogel WV. The increasing potential of nuclear medicine imaging for the evaluation and reduction of normal tissue toxicity from radiation treatments. Eur J Nucl Med Mol Imaging 2021. [PMID: 33687522 DOI: 10.1007/s00259-021-05284-5] [Reference Citation Analysis]
115 Chen LC, Chiou WY, Lin HY, Lee MS, Lo YC, Huang LW, Chang CM, Hung TH, Lin CW, Tseng KC, Liu DW, Hsu FC, Hung SK. Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial. BMC Cancer 2019;19:275. [PMID: 30922261 DOI: 10.1186/s12885-019-5461-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
116 Jones DA, Smith J, Mei XW, Hawkins MA, Maughan T, van den Heuvel F, Mee T, Kirkby K, Kirkby N, Gray A. A systematic review of health economic evaluations of proton beam therapy for adult cancer: Appraising methodology and quality. Clin Transl Radiat Oncol 2020;20:19-26. [PMID: 31754652 DOI: 10.1016/j.ctro.2019.10.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
117 Lee SU, Park JW, Kim TH, Kim YJ, Woo SM, Koh YH, Lee WJ, Park SJ, Kim DY, Kim CM. Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Strahlenther Onkol. 2014;190:806-814. [PMID: 24589917 DOI: 10.1007/s00066-014-0604-6] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
118 Schaub SK, Hartvigson PE, Lock MI, Høyer M, Brunner TB, Cardenes HR, Dawson LA, Kim EY, Mayr NA, Lo SS, Apisarnthanarax S. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies. Technol Cancer Res Treat 2018;17:1533033818790217. [PMID: 30068240 DOI: 10.1177/1533033818790217] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
119 Lo CH, Huang WY, Hsiang CW, Lee MS, Lin CS, Yang JF, Hsu HH, Chang WC. Prognostic Significance of Apparent Diffusion Coefficient in Hepatocellular Carcinoma Patients treated with Stereotactic Ablative Radiotherapy. Sci Rep 2019;9:14157. [PMID: 31578433 DOI: 10.1038/s41598-019-50503-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
120 Hijazi H, Campeau MP, Roberge D, Donath D, Lapointe R, Vandenbroucke-Menu F, Taussky D, Boudam K, Chan G, Bujold A, Delouya G. Stereotactic Body Radiotherapy for Inoperable Liver Tumors: Results of a Single Institutional Experience. Cureus 2016;8:e935. [PMID: 28123916 DOI: 10.7759/cureus.935] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
121 Yeh MM, Yeung RS, Apisarnthanarax S, Bhattacharya R, Cuevas C, Harris WP, Hon TLK, Padia SA, Park JO, Riggle KM, Daoud SS. Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience. World J Hepatol 2015; 7(11): 1460-1483 [PMID: 26085907 DOI: 10.4254/wjh.v7.i11.1460] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
122 Rosenberg SA, Henke LE, Shaverdian N, Mittauer K, Wojcieszynski AP, Hullett CR, Kamrava M, Lamb J, Cao M, Green OL, Kashani R, Paliwal B, Bayouth J, Harari PM, Olsen JR, Lee P, Parikh PJ, Bassetti M. A Multi-Institutional Experience of MR-Guided Liver Stereotactic Body Radiation Therapy. Adv Radiat Oncol 2019;4:142-9. [PMID: 30706022 DOI: 10.1016/j.adro.2018.08.005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 11.3] [Reference Citation Analysis]
123 Imada S, Ishiyama K, Ide K, Kobayashi T, Amano H, Tashiro H, Arihiro K, Aikata H, Chayama K, Ohdan H. Inferior vena cava tumor thrombus that directly infiltrated from paracaval lymph node metastases in a patient with recurrent hepatocellular carcinoma. World J Surg Oncol 2013;11:177. [PMID: 23915104 DOI: 10.1186/1477-7819-11-177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
124 Yu JI, Park HC. Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2016; 22(30): 6851-6863 [PMID: 27570422 DOI: 10.3748/wjg.v22.i30.6851] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
125 Toesca DAS, Ibragimov B, Koong AJ, Xing L, Koong AC, Chang DT. Strategies for prediction and mitigation of radiation-induced liver toxicity. J Radiat Res 2018;59:i40-9. [PMID: 29432550 DOI: 10.1093/jrr/rrx104] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
126 Rim CH, Yoon WS. Leaflet manual of external beam radiation therapy for hepatocellular carcinoma: a review of the indications, evidences, and clinical trials. Onco Targets Ther. 2018;11:2865-2874. [PMID: 29844684 DOI: 10.2147/ott.s164651] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
127 Raees A, Kamran M, Özkan H, Jafri W. Updates on the Diagnosis and Management of Hepatocellular Carcinoma. Euroasian J Hepatogastroenterol 2021;11:32-40. [PMID: 34316462 DOI: 10.5005/jp-journals-10018-1335] [Reference Citation Analysis]
128 Shui Y, Yu W, Ren X, Guo Y, Xu J, Ma T, Zhang B, Wu J, Li Q, Hu Q, Shen L, Bai X, Liang T, Wei Q. Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis. Radiat Oncol 2018;13:188. [PMID: 30253783 DOI: 10.1186/s13014-018-1136-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
129 Romesser PB, Tyagi N, Crane CH. Magnetic Resonance Imaging-Guided Adaptive Radiotherapy for Colorectal Liver Metastases. Cancers (Basel) 2021;13:1636. [PMID: 33915810 DOI: 10.3390/cancers13071636] [Reference Citation Analysis]
130 McNamara MG, Knox JJ. Systemic therapy for hepatocellular carcinoma. Hepat Oncol 2014;1:23-38. [PMID: 30190939 DOI: 10.2217/hep.13.10] [Reference Citation Analysis]
131 Wong W, Cheung C, Mak C. Early experience of transarterial chemoembolization and stereotactic body radiotherapy as neoadjuvant therapy in treating solitary right-lobe hepatocellular carcinoma greater than 10 cm: Large right lobe hepatocellular carcinoma. Surgical Practice 2016;20:43-8. [DOI: 10.1111/1744-1633.12161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
132 Vilarinho S, Taddei T. Therapeutic strategies for hepatocellular carcinoma: new advances and challenges. Curr Treat Options Gastroenterol 2015;13:219-34. [PMID: 25791207 DOI: 10.1007/s11938-015-0049-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
133 Liu X, Song Y, Liang P, Su T, Zhang H, Zhao X, Yuan Z, Wang P. Analysis of the factors affecting the safety of robotic stereotactic body radiation therapy for hepatocellular carcinoma patients. Onco Targets Ther 2017;10:5289-95. [PMID: 29158680 DOI: 10.2147/OTT.S142025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
134 Sheng H, Huang Y, Xiao Y, Zhu Z, Shen M, Zhou P, Guo Z, Wang J, Wang H, Dai W, Zhang W, Sun J, Cao C. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. J Immunother Cancer 2020;8:e000340. [PMID: 32461345 DOI: 10.1136/jitc-2019-000340] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 20.0] [Reference Citation Analysis]
135 Klein J, Dawson LA, Tran TH, Adeyi O, Purdie T, Sherman M, Brade A. Metabolic syndrome-related hepatocellular carcinoma treated by volumetric modulated arc therapy. Curr Oncol 2014;21:e340-4. [PMID: 24764717 DOI: 10.3747/co.21.1756] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
136 Cao N, Cai HJ, Sun XX, Liu DL, Huang B. Application of curved ablation in liver cancer with special morphology or location: Report of two cases. World J Clin Cases 2020; 8(9): 1713-1720 [PMID: 32420306 DOI: 10.12998/wjcc.v8.i9.1713] [Reference Citation Analysis]
137 Gallicchio R, Nardelli A, Mainenti P, Nappi A, Capacchione D, Simeon V, Sirignano C, Abbruzzi F, Barbato F, Landriscina M. Therapeutic Strategies in HCC: Radiation Modalities. Biomed Res Int. 2016;2016:1295329. [PMID: 27563661 DOI: 10.1155/2016/1295329] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
138 Herren JL, Disomma N, Ray CE Jr. Hepatocellular Carcinoma: Combined Transarterial Chemoembolization and Ablation. Semin Intervent Radiol 2019;36:279-84. [PMID: 31435137 DOI: 10.1055/s-0039-1694066] [Reference Citation Analysis]
139 Riou O, Valdenaire S, Debuire P, Fenoglietto P, Debrigode C, Mazard T, Assenat É, Aillères N, Azria D. [Liver stereotactic body radiotherapy: Clinical features and technical consequences, results. Which treatment machine in which situation?]. Cancer Radiother 2019;23:636-50. [PMID: 31444078 DOI: 10.1016/j.canrad.2019.07.159] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
140 Rio E, Mornex F, Maingon P, Peiffert D, Parent L. Hepatic tumours and radiotherapy. Cancer Radiother 2021:S1278-3218(21)00202-X. [PMID: 34953707 DOI: 10.1016/j.canrad.2021.08.013] [Reference Citation Analysis]
141 Cuneo KC, Morgan MA, Davis MA, Parcels LA, Parcels J, Karnak D, Ryan C, Liu N, Maybaum J, Lawrence TS. Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress. Int J Radiat Oncol Biol Phys. 2016;95:782-790. [PMID: 26975930 DOI: 10.1016/j.ijrobp.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
142 Lewis S, Barry A, Hawkins M. Hypofractionation in Hepatocellular Carcinoma – The Effect of Fractionation Size. Clinical Oncology 2022. [DOI: 10.1016/j.clon.2022.02.021] [Reference Citation Analysis]
143 Funaoka A, Numata K, Takeda A, Saigusa Y, Tsurugai Y, Nihonmatsu H, Chuma M, Fukuda H, Okada M, Nakano M, Maeda S. Use of Contrast-Enhanced Ultrasound with Sonazoid for Evaluating the Radiotherapy Efficacy for Hepatocellular Carcinoma. Diagnostics (Basel) 2021;11:486. [PMID: 33803373 DOI: 10.3390/diagnostics11030486] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Debbi K, Janoray G, Scher N, Deutsch É, Mornex F. [Doses to organs at risk in conformational and stereotactic body radiation therapy: Liver]. Cancer Radiother 2017;21:604-12. [PMID: 28893525 DOI: 10.1016/j.canrad.2017.07.042] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
145 Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms. Z Gastroenterol 2022;60:e56-e130. [PMID: 35042248 DOI: 10.1055/a-1589-7568] [Reference Citation Analysis]
146 Pan YX, Xi M, Fu YZ, Hu DD, Wang JC, Liu SL, Chen JB, Xu L, Zhou ZG, Liu MZ, Chen MS, Zhao L, Zhang YJ. Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Propensity Score Matching Study. Cancers (Basel) 2019;11:E1116. [PMID: 31387248 DOI: 10.3390/cancers11081116] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
147 Gupta A, Kumar R, Yadav HP, Sharma M, Kamal R, Thaper D, Banik P, Gupta S, Saroha K, Singh S, Kumar Sarin S. Feasibility of 4D CT simulation with synchronized intravenous contrast injection in hepatocellular carcinoma. Rep Pract Oncol Radiother 2020;25:293-8. [PMID: 32194348 DOI: 10.1016/j.rpor.2019.12.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
148 Willatt J, Hannawa KK, Ruma JA, Frankel TL, Owen D, Barman PM. Image-guided therapies in the treatment of hepatocellular carcinoma: A multidisciplinary perspective. World J Hepatol 2015; 7(2): 235-244 [PMID: 25729478 DOI: 10.4254/wjh.v7.i2.235] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
149 Lock MI, Klein J, Chung HT, Herman JM, Kim EY, Small W, Mayr NA, Lo SS. Strategies to tackle the challenges of external beam radiotherapy for liver tumors. World J Hepatol 2017; 9(14): 645-656 [PMID: 28588749 DOI: 10.4254/wjh.v9.i14.645] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
150 Abdel-Rahman O, Elsayed Z. External beam radiotherapy for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2017;3:CD011314. [PMID: 28267205 DOI: 10.1002/14651858.CD011314.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
151 Park J, Jung J, Kim D, Jung IH, Park JH, Kim JH, Lee SW, Yoon SM. Long-term outcomes of the 2-week schedule of hypofractionated radiotherapy for recurrent hepatocellular carcinoma. BMC Cancer 2018;18:1040. [PMID: 30367606 DOI: 10.1186/s12885-018-4953-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
152 Francis S, Williams N, Anker CJ, Shaaban A, Kim R, Shrieve D, Tward J. Stereotactic Body Radiotherapy for Hepatocellular Carcinoma Resulting in a Durable Relapse-Free Survival: A Case Report. Cureus 2016;8:e841. [PMID: 27909629 DOI: 10.7759/cureus.841] [Reference Citation Analysis]
153 Hilal L, Reyngold M, Wu AJ, Araji A, Abou-Alfa GK, Jarnagin W, Harding JJ, Gambarin M, El Dika I, Brady P, Navilio J, Berry SL, Flynn J, Zhang Z, Tuli R, Zinovoy M, Romesser PB, Cuaron JJ, Crane CH, Hajj C. Ablative radiation therapy for hepatocellular carcinoma is associated with reduced treatment- and tumor-related liver failure and improved survival. J Gastrointest Oncol 2021;12:1743-52. [PMID: 34532124 DOI: 10.21037/jgo-21-116] [Reference Citation Analysis]
154 Suresh K, Owen D, Bazzi L, Jackson W, Ten Haken RK, Cuneo K, Feng M, Lawrence TS, Schipper MJ. Using Indocyanine Green Extraction to Predict Liver Function After Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2018;100:131-7. [PMID: 29128147 DOI: 10.1016/j.ijrobp.2017.09.032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
155 Mokdad AA, Singal AG, Yopp AC. Advances in Local and Systemic Therapies for Hepatocellular Cancer. Curr Oncol Rep 2016;18:9. [PMID: 26769114 DOI: 10.1007/s11912-015-0494-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
156 Marqueen KE, Kim E, Ang C, Mazumdar M, Buckstein M, Ferket BS. Cost-Effectiveness Analysis of Selective Internal Radiotherapy With Yttrium-90 Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma. JCO Oncol Pract 2021;17:e266-77. [PMID: 33417490 DOI: 10.1200/OP.20.00443] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
157 Wahl DR, Schipper MJ, Parikh ND, Owen D, Lawrence TS. Casual Causality: Does Radiofrequency Ablation Really Prolong Survival After Treatment of Localized Hepatocellular Carcinoma? J Clin Oncol 2018;36:2559-60. [PMID: 29945526 DOI: 10.1200/JCO.2018.78.0882] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
158 Zhang HJ, Zhu XF. Clinical implementation of stereotactic body radiation therapy in pancreatic cancer and hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2015; 23(25): 3989-3996 [DOI: 10.11569/wcjd.v23.i25.3989] [Reference Citation Analysis]
159 Park S, Rim CH, Yoon WS. Where is clinical research for radiotherapy going? Cross-sectional comparison of past and contemporary phase III clinical trials. Radiat Oncol 2020;15:36. [PMID: 32059729 DOI: 10.1186/s13014-020-01489-4] [Reference Citation Analysis]
160 Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Goyal L, Murphy JE, Javle MM, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Yoon SS, Tanabe KK, Ferrone CR, Ryan DP, DeLaney TF, Crane CH, Zhu AX. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol. 2016;34:460-468. [PMID: 26668346 DOI: 10.1200/jco.2015.64.2710] [Cited by in Crossref: 209] [Cited by in F6Publishing: 106] [Article Influence: 29.9] [Reference Citation Analysis]
161 Hsieh CH, Lin SC, Shueng PW, Kuo DY. Recall radiation dermatitis by sorafenib following stereotactic body radiation therapy. Onco Targets Ther 2014;7:1111-4. [PMID: 24971021 DOI: 10.2147/OTT.S64706] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
162 Mohamad O, Sishc BJ, Saha J, Pompos A, Rahimi A, Story MD, Davis AJ, Kim DWN. Carbon Ion Radiotherapy: A Review of Clinical Experiences and Preclinical Research, with an Emphasis on DNA Damage/Repair. Cancers (Basel) 2017;9:E66. [PMID: 28598362 DOI: 10.3390/cancers9060066] [Cited by in Crossref: 73] [Cited by in F6Publishing: 52] [Article Influence: 14.6] [Reference Citation Analysis]
163 Zhao YT, Liu ZK, Wu QW, Dai JR, Zhang T, Jia AY, Jin J, Wang SL, Li YX, Wang WH. Observation of different tumor motion magnitude within liver and estimate of internal motion margins in postoperative patients with hepatocellular carcinoma. Cancer Manag Res 2017;9:839-48. [PMID: 29276406 DOI: 10.2147/CMAR.S147185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
164 Tchelebi LT, Haustermans K, Scorsetti M, Hosni A, Huguet F, Hawkins MA, Dawson LA, Goodman KA. Recommendations for the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19. Radiother Oncol. 2020;148:194-200. [PMID: 32342878 DOI: 10.1016/j.radonc.2020.04.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 13.5] [Reference Citation Analysis]
165 Donadon M, Solbiati L, Dawson L, Barry A, Sapisochin G, Greig PD, Shiina S, Fontana A, Torzilli G. Hepatocellular Carcinoma: The Role of Interventional Oncology. Liver Cancer. 2016;6:34-43. [PMID: 27995086 DOI: 10.1159/000449346] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
166 Sun X, Deng L, Lu Y. Challenges and opportunities of using stereotactic body radiotherapy with anti-angiogenesis agents in tumor therapy. Chin J Cancer Res 2018;30:147-56. [PMID: 29545728 DOI: 10.21147/j.issn.1000-9604.2018.01.15] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
167 Srivastava A, Parambath HK, Ramdulari AV, Saxena H, Kumar R, Pandey S, Shalimar, Gupta S, Jee B. Is hepatocellular carcinoma complicated with portal vein tumor thrombosis potentially curable by radiotherapy in the form of stereotactic body radiation therapy? Int J Radiat Biol 2022;:1-15. [PMID: 35311612 DOI: 10.1080/09553002.2022.2055800] [Reference Citation Analysis]
168 Tanaka O, Kojima T, Ohbora A, Makita C, Taniguchi T, Ono K, Matsuo M, Nagata Y. Scores of Child-Pugh Classification Impact Overall Survival After Stereotactic Body Radiation Therapy for Primary and Metastatic Liver Tumors. J Clin Exp Hepatol 2020;10:101-5. [PMID: 32189924 DOI: 10.1016/j.jceh.2019.05.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
169 Zhang S, He L, Bo C, Yang S, An Y, Li N, Zhao Y, Zhao L, Ma W, Zheng Z. Comparison of stereotactic body radiation therapy versus fractionated radiation therapy for primary liver cancer with portal vein tumor thrombus. Radiat Oncol 2021;16:149. [PMID: 34391452 DOI: 10.1186/s13014-021-01874-7] [Reference Citation Analysis]
170 Habermehl D, Combs SE. [Stereotactic body radiotherapy for the treatment of hepatocellular cancer. Pooled analysis of two phase I/II trials]. Strahlenther Onkol 2013;189:1051-3. [PMID: 24158636 DOI: 10.1007/s00066-013-0449-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
171 Labadie KP, Schaub SK, Khorsand D, Johnson G, Apisarnthanarax S, Park JO. Multidisciplinary approach for multifocal, bilobar hepatocellular carcinoma: A case report and literature review. World J Hepatol 2019; 11(1): 119-126 [PMID: 30705724 DOI: 10.4254/wjh.v11.i1.119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
172 Arscott WT, Thompson RF, Yin L, Burgdorf B, Kirk M, Ben-Josef E. Stereotactic body proton therapy for liver tumors: Dosimetric advantages and their radiobiological and clinical implications. Phys Imaging Radiat Oncol 2018;8:17-22. [PMID: 33458411 DOI: 10.1016/j.phro.2018.11.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
173 Yoon SM, Ryoo BY, Lee SJ, Kim JH, Shin JH, An JH, Lee HC, Lim YS. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial. JAMA Oncol. 2018;4:661-669. [PMID: 29543938 DOI: 10.1001/jamaoncol.2017.5847] [Cited by in Crossref: 130] [Cited by in F6Publishing: 113] [Article Influence: 43.3] [Reference Citation Analysis]
174 Thomas TO, Hasan S, Small W Jr, Herman JM, Lock M, Kim EY, Mayr NA, Teh BS, Lo SS. The tolerance of gastrointestinal organs to stereotactic body radiation therapy: what do we know so far? J Gastrointest Oncol. 2014;5:236-246. [PMID: 24982772 DOI: 10.3978/j.issn.2078-6891.2014.024] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
175 Bibault JE, Dewas S, Vautravers-Dewas C, Hollebecque A, Jarraya H, Lacornerie T, Lartigau E, Mirabel X. Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity. PLoS One. 2013;8:e77472. [PMID: 24147002 DOI: 10.1371/journal.pone.0077472] [Cited by in Crossref: 76] [Cited by in F6Publishing: 66] [Article Influence: 8.4] [Reference Citation Analysis]
176 Crane CH, Koay EJ. Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance. Cancer. 2016;122:1974-1986. [PMID: 26950735 DOI: 10.1002/cncr.29878] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 8.7] [Reference Citation Analysis]
177 Jiang C, Jing S, Zhou H, Li A, Qiu X, Zhu X, Shen Z. Efficacy and Prognostic Factors of Trans-Arterial Chemoembolization Combined With Stereotactic Body Radiation Therapy for BCLC Stage B Hepatocellular Carcinoma. Front Oncol 2021;11:640461. [PMID: 34336647 DOI: 10.3389/fonc.2021.640461] [Reference Citation Analysis]
178 Jeong Y, Jung J, Cho B, Kwak J, Jeong C, Kim JH, Park JH, Kim SY, Shim JH, Kim KM, Lim YS, Lee HC, Yoon SM. Stereotactic body radiation therapy using a respiratory-gated volumetric-modulated arc therapy technique for small hepatocellular carcinoma. BMC Cancer. 2018;18:416. [PMID: 29653562 DOI: 10.1186/s12885-018-4340-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
179 Zeng ZC, Seong J, Yoon SM, Cheng JC, Lam KO, Lee AS, Law A, Zhang JY, Hu Y. Consensus on Stereotactic Body Radiation Therapy for Small-Sized Hepatocellular Carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting. Liver Cancer. 2017;6:264-274. [PMID: 29234630 DOI: 10.1159/000475768] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
180 Sun N, Zhang J, Li B, Li A, Lv M, Zhang C. Favorable response to multimodal treatment in hepatocellular carcinoma with inferior vena cava and right atrial tumor thrombus and left adrenal gland metastasis: A case report and literature review. Medicine (Baltimore) 2021;100:e27987. [PMID: 34889243 DOI: 10.1097/MD.0000000000027987] [Reference Citation Analysis]
181 Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 96] [Cited by in F6Publishing: 108] [Article Influence: 96.0] [Reference Citation Analysis]
182 Mak SH, Wong SMN, Chiu WHK, Chiang CL, Yip WLW, Ho HMC, Yeung SYC, Chan KHM, Lee WYV, Lee ASF. Presence of tumour capsule on contrast-enhanced CT is associated with improved outcomes of stereotactic body radiation therapy in hepatocellular carcinoma patients. Strahlenther Onkol 2022. [PMID: 34988623 DOI: 10.1007/s00066-021-01879-x] [Reference Citation Analysis]
183 Wahl DR, Tao Y, Schipper M, Lawrence TS, Feng M. Reply to Yang et al and De Bari et al. J Clin Oncol 2016;34:2799. [PMID: 27325853 DOI: 10.1200/JCO.2016.67.7492] [Reference Citation Analysis]
184 Au KP, Chok KSH. Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm. World J Gastroenterol 2018; 24(45): 5081-5094 [PMID: 30568386 DOI: 10.3748/wjg.v24.i45.5081] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
185 Kamimura K, Terai S. The promise of radiotherapy for hepatocellular carcinoma. Hepatol Res 2021;51:837-8. [PMID: 34346128 DOI: 10.1111/hepr.13687] [Reference Citation Analysis]
186 Pursley J, El Naqa I, Sanford NN, Noe B, Wo JY, Eyler CE, Hwang M, Brock KK, Yeap BY, Wolfgang JA, Hong TS, Grassberger C. Dosimetric Analysis and Normal-Tissue Complication Probability Modeling of Child-Pugh Score and Albumin-Bilirubin Grade Increase After Hepatic Irradiation. Int J Radiat Oncol Biol Phys 2020;107:986-95. [PMID: 32353390 DOI: 10.1016/j.ijrobp.2020.04.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
187 Gomez-Puerto D, Mirallas O, Vidal-González J, Vargas V. Hepatocellular carcinoma with tumor thrombus extends to the right atrium and portal vein: A case report. World J Hepatol 2020; 12(11): 1128-1135 [PMID: 33312435 DOI: 10.4254/wjh.v12.i11.1128] [Reference Citation Analysis]
188 Shi F, Wang C, Kong Y, Yang L, Li J, Zhu G, Guo J, Zheng Q, Zhang B, Wang S. Assessing the Survival Benefit of Surgery and Various Types of Radiation Therapy for Treatment of Hepatocellular Carcinoma: Evidence from the Surveillance, Epidemiology, and End Results Registries. J Hepatocell Carcinoma 2020;7:201-18. [PMID: 33117754 DOI: 10.2147/JHC.S272813] [Reference Citation Analysis]
189 Moore A, Cohen-Naftaly M, Tobar A, Kundel Y, Benjaminov O, Braun M, Issachar A, Mor E, Sarfaty M, Bragilovski D, Hur RB, Gordon N, Stemmer SM, Allen AM. Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma. Radiat Oncol. 2017;12:163. [PMID: 29052532 DOI: 10.1186/s13014-017-0899-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
190 Yamoah K, Showalter TN, Ohri N. Radiation Therapy Intensification for Solid Tumors: A Systematic Review of Randomized Trials. Int J Radiat Oncol Biol Phys. 2015;93:737-745. [PMID: 26530740 DOI: 10.1016/j.ijrobp.2015.07.2284] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
191 Chamseddine I, Kim Y, De B, El Naqa I, Duda DG, Wolfgang J, Pursley J, Paganetti H, Wo J, Hong T, Koay EJ, Grassberger C. Predictive Modeling of Survival and Toxicity in Patients With Hepatocellular Carcinoma After Radiotherapy. JCO Clin Cancer Inform 2022;6:e2100169. [PMID: 35192402 DOI: 10.1200/CCI.21.00169] [Reference Citation Analysis]
192 Bae SH, Kim MS, Jang WI, Cho CK, Yoo HJ, Kim KB, Han CJ, Park SC, Lee DH. Low Hepatic Toxicity in Primary and Metastatic Liver Cancers after Stereotactic Ablative Radiotherapy Using 3 Fractions. J Korean Med Sci 2015;30:1055-61. [PMID: 26240482 DOI: 10.3346/jkms.2015.30.8.1055] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
193 Krug D, Hofheinz R, Gkika E, Brunner T, Boda-Heggemann J. [Unexpectedly high mortality after surgical liver interventions in Germany]. Strahlenther Onkol 2020;196:98-100. [PMID: 31732781 DOI: 10.1007/s00066-019-01547-1] [Reference Citation Analysis]
194 Chuong MD, Kaiser A, Khan F, Parikh P, Ben-Josef E, Crane C, Brunner T, Okumura T, Schreuder N, Bentzen SM, Gutierrez A, Mendez Romero A, Yoon SM, Sharma N, Kim TH, Kishi K, Moeslein F, Hoffe S, Schefter T, Hanish S, Scorsetti M, Apisarnthanarax S. Consensus Report From the Miami Liver Proton Therapy Conference. Front Oncol. 2019;9:457. [PMID: 31214502 DOI: 10.3389/fonc.2019.00457] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
195 Choi C, Choi GH, Kim TH, Tanaka M, Meng MB, Seong J. Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. Liver Cancer 2014;3:405-16. [PMID: 26280002 DOI: 10.1159/000343861] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
196 Sanuki N, Takeda A, Kunieda E. Role of stereotactic body radiation therapy for hepatocellular carcinoma. World J Gastroenterol 2014; 20(12): 3100-3111 [PMID: 24696597 DOI: 10.3748/wjg.v20.i12.3100] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
197 Pollom EL, Deng L, Pai RK, Brown JM, Giaccia A, Loo BW Jr, Shultz DB, Le QT, Koong AC, Chang DT. Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 2015;92:568-76. [PMID: 26068491 DOI: 10.1016/j.ijrobp.2015.02.016] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 5.7] [Reference Citation Analysis]
198 Matoba M, Tsuchiya H, Kondo T, Ota K. Stereotactic body radiotherapy delivered with IMRT for oligometastatic regional lymph node metastases in hepatocellular carcinoma: a single-institutional study. J Radiat Res. 2020;61:776-783. [PMID: 32845298 DOI: 10.1093/jrr/rraa067] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
199 Bettinger D, Gkika E, Schultheiss M, Glaser N, Lange S, Maruschke L, Buettner N, Kirste S, Nestle U, Grosu AL, Thimme R, Brunner TB. Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis. BMC Cancer 2018;18:807. [PMID: 30092781 DOI: 10.1186/s12885-018-4696-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
200 Weiner AA, Olsen J, Ma D, Dyk P, DeWees T, Myerson RJ, Parikh P. Stereotactic body radiotherapy for primary hepatic malignancies - Report of a phase I/II institutional study. Radiother Oncol 2016;121:79-85. [PMID: 27566894 DOI: 10.1016/j.radonc.2016.07.020] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 7.3] [Reference Citation Analysis]
201 Buckstein M, Kim E, Fischman A, Blacksburg S, Facciuto M, Schwartz M, Rosenzweig K. Stereotactic body radiation therapy following transarterial chemoembolization for unresectable hepatocellular carcinoma. J Gastrointest Oncol 2018;9:734-40. [PMID: 30151270 DOI: 10.21037/jgo.2018.05.01] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
202 Zhang X, Yang DY, Wang C, Huang L. Characteristics of stereotactic radiotherapy clinical trials registered on ClinicalTrials.gov. Transl Cancer Res 2021;10:4316-26. [PMID: 35116290 DOI: 10.21037/tcr-21-1189] [Reference Citation Analysis]
203 Hasan S, Renz P, Packard M, Horrigan S, Gresswell S, Kirichenko AV. Effect of Daily and Every Other Day Stereotactic Body Radiation Therapy Schedules on Treatment-Related Fatigue in Patients With Hepatocellular Carcinoma. Pract Radiat Oncol 2019;9:e38-45. [PMID: 30612721 DOI: 10.1016/j.prro.2018.06.005] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
204 Imaeda M, Ishikawa H, Yoshida Y, Takahashi T, Ohkubo Y, Musha A, Komachi M, Nakazato Y, Nakano T. Long-term pathological and immunohistochemical features in the liver after intraoperative whole-liver irradiation in rats. J Radiat Res 2014;55:665-73. [PMID: 24566720 DOI: 10.1093/jrr/rru005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
205 Park SH, Kim JC, Kang MK. Technical advances in external radiotherapy for hepatocellular carcinoma. World J Gastroenterol 2016; 22(32): 7311-7321 [PMID: 27621577 DOI: 10.3748/wjg.v22.i32.7311] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
206 Fukuda K, Okumura T, Abei M, Fukumitsu N, Ishige K, Mizumoto M, Hasegawa N, Numajiri H, Ohnishi K, Ishikawa H. Long-term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma. Cancer Sci. 2017;108:497-503. [PMID: 28012214 DOI: 10.1111/cas.13145] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
207 Tanguturi SK, Wo JY, Zhu AX, Dawson LA, Hong TS. Radiation therapy for liver tumors: ready for inclusion in guidelines? Oncologist. 2014;19:868-879. [PMID: 25001265 DOI: 10.1634/theoncologist.2014-0097] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
208 Jacob R, Turley F, Redden DT, Saddekni S, Aal AK, Keene K, Yang E, Zarzour J, Bolus D, Smith JK. Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥ 3 cm. HPB (Oxford). 2015;17:140-149. [PMID: 25186290 DOI: 10.1111/hpb.12331] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 5.3] [Reference Citation Analysis]
209 Sørensen M, Fode MM, Petersen JB, Holt MI, Høyer M. Effect of stereotactic body radiotherapy on regional metabolic liver function investigated in patients by dynamic [18F]FDGal PET/CT. Radiat Oncol 2021;16:192. [PMID: 34598730 DOI: 10.1186/s13014-021-01909-z] [Reference Citation Analysis]
210 Fu Y, Xi M, Pan Y, Chen J, Wang J, Liu S, Xu L, Zhou Z, Liu M, Chen M, Zhao L, Zhang Y. Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Cohort Study. J Oncol 2020;2020:4835653. [PMID: 32565803 DOI: 10.1155/2020/4835653] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
211 Tabchouri N, Bucur P, Salamé E. Comment on: prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant. Hepatobiliary Surg Nutr 2021;10:510-1. [PMID: 34430530 DOI: 10.21037/hbsn-21-287] [Reference Citation Analysis]
212 Benson AB 3rd, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017;15:563-573. [PMID: 28476736 DOI: 10.6004/jnccn.2017.0059] [Cited by in Crossref: 155] [Cited by in F6Publishing: 149] [Article Influence: 31.0] [Reference Citation Analysis]
213 Choi SH, Seong J. Strategic Application of Radiotherapy for Hepatocellular Carcinoma. Clin Mol Hepatol. 2018; Epub ahead of print. [PMID: 29439305 DOI: 10.3350/cmh.2017.0073] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
214 Cheng CW, Machtay M, Dorth J, Sergeeva O, Xia H, Manaspon C, Wu H, Iyer R, Sexton S, Xin W, Exner AA, Lee Z. Delayed response to proton beam treatment of hepatocellular carcinoma. BJR Case Rep. 2020;6:20180125. [PMID: 32201597 DOI: 10.1259/bjrcr.20180125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
215 Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS, Schipper MJ, Feng M. Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma. J Clin Oncol. 2016;34:452-459. [PMID: 26628466 DOI: 10.1200/jco.2015.61.4925] [Cited by in Crossref: 259] [Cited by in F6Publishing: 112] [Article Influence: 37.0] [Reference Citation Analysis]
216 Lee P, Ma Y, Zacharias I, Bozorgzadeh A, Wilson S, Foley K, Rava P, Masciocchi M, Ding L, Bledsoe J, Fitzgerald TJ, Sioshansi S. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in Patients With Child-Pugh B or C Cirrhosis. Adv Radiat Oncol 2020;5:889-96. [PMID: 33083650 DOI: 10.1016/j.adro.2020.01.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 Kim TH, Park JW, Kim BH, Oh ES, Youn SH, Moon SH, Kim SS, Woo SM, Koh YH, Lee WJ, Kim DY. Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma. Front Oncol 2020;10:542. [PMID: 32411594 DOI: 10.3389/fonc.2020.00542] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
218 Shinoto M, Ebner DK, Yamada S. Particle Radiation Therapy for Gastrointestinal Cancers. Curr Oncol Rep 2016;18:17. [PMID: 26849660 DOI: 10.1007/s11912-016-0499-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
219 Jackson WC, Suresh K, Maurino C, Feng M, Cuneo KC, Ten Haken RK, Lawrence TS, Schipper MJ, Owen D. A mid-treatment break and reassessment maintains tumor control and reduces toxicity in patients with hepatocellular carcinoma treated with stereotactic body radiation therapy. Radiother Oncol 2019;141:101-7. [PMID: 31431377 DOI: 10.1016/j.radonc.2019.07.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
220 Yacoub JH, Mauro D, Moon A, He AR, Bashir MR, Hsu CC, Fishbein TM, Burke LMB. Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention. Abdom Radiol (NY) 2021;46:3540-8. [PMID: 33864107 DOI: 10.1007/s00261-021-03074-z] [Reference Citation Analysis]
221 Likhitsup A, Parikh ND. Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians. Pharmacoeconomics 2020;38:5-24. [PMID: 31573053 DOI: 10.1007/s40273-019-00839-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
222 Bae SH, Park HC. Local modalities for inoperable hepatocellular carcinoma: radiofrequency ablation versus stereotactic body radiotherapy. Ann Transl Med 2018;6:S3. [PMID: 30613579 DOI: 10.21037/atm.2018.08.28] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
223 Lee HL, Tsai JT, Chen CY, Lin YC, Ho CB, Ting LL, Kuo CC, Lai IC, Lin CY, Tang JH, Huang YM, Kao WY, Cheng SW, Shen CN, Chen SW, Chiou JF. Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization. Ther Adv Med Oncol 2019;11:1758835919889002. [PMID: 31839809 DOI: 10.1177/1758835919889002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
224 Tong VJW, Shelat VG, Chao YK. Clinical application of advances and innovation in radiation treatment of hepatocellular carcinoma. J Clin Transl Res 2021;7:811-33. [PMID: 34988334] [Reference Citation Analysis]
225 Hong JC, Ayala-Peacock DN, Lee J, Blackstock AW, Okunieff P, Sung MW, Weichselbaum RR, Kao J, Urbanic JJ, Milano MT, Chmura SJ, Salama JK. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis. PLoS One 2018;13:e0195149. [PMID: 29649281 DOI: 10.1371/journal.pone.0195149] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 12.8] [Reference Citation Analysis]
226 Kato H, Yoshida H, Taniguch H, Nomura R, Sato K, Suzuki I, Nakata R. Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma. World J Gastroenterol 2015; 21(46): 13101-13112 [PMID: 26673627 DOI: 10.3748/wjg.v21.i46.13101] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
227 Shiba S, Abe T, Shibuya K, Katoh H, Koyama Y, Shimada H, Kakizaki S, Shirabe K, Kuwano H, Ohno T, Nakano T. Carbon ion radiotherapy for 80 years or older patients with hepatocellular carcinoma. BMC Cancer 2017;17:721. [PMID: 29115938 DOI: 10.1186/s12885-017-3724-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
228 Park HC, Yu JI, Cheng JC, Zeng ZC, Hong JH, Wang ML, Kim MS, Chi KH, Liang PC, Lee RC, Lau WY, Han KH, Chow PK, Seong J. Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials. Liver Cancer. 2016;5:162-174. [PMID: 27493892 DOI: 10.1159/000367766] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
229 Mathew AS, Atenafu EG, Owen D, Maurino C, Brade A, Brierley J, Dinniwell R, Kim J, Cho C, Ringash J, Wong R, Cuneo K, Feng M, Lawrence TS, Dawson LA. Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion. Eur J Cancer 2020;134:41-51. [PMID: 32460180 DOI: 10.1016/j.ejca.2020.04.024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
230 Keane FK, Tanguturi SK, Zhu AX, Dawson LA, Hong TS. Radiotherapy for liver tumors. Hepat Oncol 2015;2:133-46. [PMID: 30190993 DOI: 10.2217/hep.15.7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
231 Li MF, Leung HW, Chan AL, Wang SY. Network meta-analysis of treatment regimens for inoperable advanced hepatocellular carcinoma with portal vein invasion. Ther Clin Risk Manag. 2018;14:1157-1168. [PMID: 30013351 DOI: 10.2147/tcrm.s162898] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
232 Brunner TB, Bettinger D, Schultheiss M, Maruschke L, Sturm L, Bartl N, Koundurdjieva I, Kirste S, Neeff HP, Goetz C, Nicolay NH, Ihorst G, Bamberg F, Thimme R, Grosu AL, Gkika E. Efficacy of Stereotactic Body Radiotherapy in Patients With Hepatocellular Carcinoma Not Suitable for Transarterial Chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical Efficacy Study). Front Oncol 2021;11:653141. [PMID: 33816309 DOI: 10.3389/fonc.2021.653141] [Reference Citation Analysis]
233 Nakayama M, Uehara K, Nishimura H, Tamura S, Munetomo Y, Tsudou S, Mayahara H, Mukumoto N, Geso M, Sasaki R. Retrospective assessment of a single fiducial marker tracking regimen with robotic stereotactic body radiation therapy for liver tumours. Rep Pract Oncol Radiother 2019;24:383-91. [PMID: 31297039 DOI: 10.1016/j.rpor.2019.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
234 Hoffman D, Mehta N. Recurrence of hepatocellular carcinoma following liver transplantation. Expert Rev Gastroenterol Hepatol 2021;15:91-102. [PMID: 32933351 DOI: 10.1080/17474124.2021.1823213] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
235 Chen ATC, Payão F, Chagas AL, De Souza Melo Alencar RS, Tani CM, da Conceição Vasconcelos KGM, de Souza Rocha M, de Andrade Carvalho H, Hoff PMG, Carrilho FJ. Feasibility of SBRT for hepatocellular carcinoma in Brazil - a prospective pilot study. Rep Pract Oncol Radiother 2021;26:226-36. [PMID: 34211773 DOI: 10.5603/RPOR.a2021.0035] [Reference Citation Analysis]
236 Krishan S, Dhiman RK, Kalra N, Sharma R, Baijal SS, Arora A, Gulati A, Eapan A, Verma A, Keshava S, Mukund A, Deva S, Chaudhary R, Ganesan K, Taneja S, Gorsi U, Gamanagatti S, Madhusudan KS, Puri P, Shalimar, Govil S, Wadhavan M, Saigal S, Kumar A, Thapar S, Duseja A, Saraf N, Khandelwal A, Mukhopadyay S, Gulati A, Shetty N, Verma N. Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System. J Clin Exp Hepatol 2019;9:625-51. [PMID: 31695253 DOI: 10.1016/j.jceh.2019.07.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
237 Kalogeridi MA, Zygogianni A, Kyrgias G, Kouvaris J, Chatziioannou S, Kelekis N, Kouloulias V. Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review. World J Hepatol 2015; 7(1): 101-112 [PMID: 25625001 DOI: 10.4254/wjh.v7.i1.101] [Cited by in Crossref: 79] [Cited by in F6Publishing: 74] [Article Influence: 11.3] [Reference Citation Analysis]
238 Bae SH, Kim MS, Jang WI, Kay CS, Kim W, Kim ES, Kim JH, Kim JH, Yang KM, Lee KC. Practical patterns for stereotactic body radiotherapy to hepatocellular carcinoma in Korea: a survey of the Korean Stereotactic Radiosurgery Group. Jpn J Clin Oncol. 2016;46:363-369. [PMID: 26826720 DOI: 10.1093/jjco/hyv209] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
239 Lee KH, Yu JI, Park HC, Park SY, Shin JS, Shin EH, Cho S, Jung SH, Han YY, Lim DH. Is higher dose always the right answer in stereotactic body radiation therapy for small hepatocellular carcinoma? Radiat Oncol J. 2018;36:129-138. [PMID: 29983033 DOI: 10.3857/roj.2017.00598] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
240 Rio E, Mornex F, Peiffert D, Huertas A. [Hepatic tumors and radiotherapy]. Cancer Radiother 2016;20 Suppl:S174-8. [PMID: 27521035 DOI: 10.1016/j.canrad.2016.07.019] [Cited by in Crossref: 6] [Article Influence: 1.0] [Reference Citation Analysis]
241 Ueno M, Takabatake H, Itasaka S, Kayahara T, Morimoto Y, Yamamoto H, Mizuno M. Stereotactic body radiation therapy versus radiofrequency ablation for single small hepatocellular carcinoma: a propensity-score matching analysis of their impact on liver function and clinical outcomes. J Gastrointest Oncol 2021;12:2334-44. [PMID: 34790396 DOI: 10.21037/jgo-21-356] [Reference Citation Analysis]
242 Shen J, Yan J, Zhu S, Kong W, Zou Z, Liu J, Li S, Liu B. The Efficacy and Safety of Hypofractionated Radiation Therapy With Tomotherapy for Advanced or Recurrent Hepatocellular Carcinoma. Front Oncol 2021;11:559112. [PMID: 34136374 DOI: 10.3389/fonc.2021.559112] [Reference Citation Analysis]
243 Huang WY, Tsai CL, Que JY, Lo CH, Lin YJ, Dai YH, Yang JF, Shen PC, Lee MH, Cheng JC. Development and Validation of a Nomogram for Patients with Nonmetastatic BCLC Stage C Hepatocellular Carcinoma after Stereotactic Body Radiotherapy. Liver Cancer 2020;9:326-37. [PMID: 32647634 DOI: 10.1159/000505693] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
244 Rabinel P, Dousse D, Muscari F, Suc B. Management of liver cancer. The Surgeon's point of view. Rep Pract Oncol Radiother 2017;22:176-80. [PMID: 28490990 DOI: 10.1016/j.rpor.2017.02.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
245 Grassberger C, Hong TS, Hato T, Yeap BY, Wo JY, Tracy M, Bortfeld T, Wolfgang JA, Eyler CE, Goyal L, Clark JW, Crane CH, Koay EJ, Cobbold M, DeLaney TF, Jain RK, Zhu AX, Duda DG. Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer. Int J Radiat Oncol Biol Phys 2018;101:1222-5. [PMID: 29859792 DOI: 10.1016/j.ijrobp.2018.04.026] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
246 Su TS, Liang P, Zhou Y, Huang Y, Cheng T, Qu S, Chen L, Xiang BD, Zhao C, Huang DJ, Liang SX, Li LQ. Stereotactic Body Radiation Therapy vs. Transarterial Chemoembolization in Inoperable Barcelona Clinic Liver Cancer Stage a Hepatocellular Carcinoma: A Retrospective, Propensity-Matched Analysis. Front Oncol 2020;10:347. [PMID: 32266136 DOI: 10.3389/fonc.2020.00347] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
247 Sayan M, Yegya-Raman N, Greco SH, Gui B, Zhang A, Chundury A, Grandhi MS, Hochster HS, Kennedy TJ, Langan RC, Malhotra U, Rustgi VK, Shah MM, Spencer KR, Carpizo DR, Nosher JL, Jabbour SK. Rethinking the Role of Radiation Therapy in the Treatment of Unresectable Hepatocellular Carcinoma: A Data Driven Treatment Algorithm for Optimizing Outcomes. Front Oncol 2019;9:345. [PMID: 31275846 DOI: 10.3389/fonc.2019.00345] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
248 Ho LT, Chen JL, Chan HM, Huang YC, Su MY, Kuo SH, Chang YC, Lin JL, Chen WJ, Lee WJ, Lin LY. First Asian population study of stereotactic body radiation therapy for ventricular arrhythmias. Sci Rep 2021;11:10360. [PMID: 33990651 DOI: 10.1038/s41598-021-89857-2] [Reference Citation Analysis]
249 Zane KE, Makary MS. Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Cancers (Basel) 2021;13:5430. [PMID: 34771593 DOI: 10.3390/cancers13215430] [Reference Citation Analysis]
250 Li X, Ye Z, Lin S, Pang H. Predictive factors for survival following stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumour thrombosis and construction of a nomogram. BMC Cancer 2021;21:701. [PMID: 34126955 DOI: 10.1186/s12885-021-08469-1] [Reference Citation Analysis]
251 Yang JF, Lo CH, Huang WY. Is Stereotactic Body Radiotherapy Better Than Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma? J Clin Oncol 2016;34:2797. [PMID: 27325860 DOI: 10.1200/JCO.2016.66.4458] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
252 Oladeru OT, Miccio JA, Yang J, Xue Y, Ryu S, Stessin AM. Conformal external beam radiation or selective internal radiation therapy-a comparison of treatment outcomes for hepatocellular carcinoma. J Gastrointest Oncol 2016;7:433-40. [PMID: 27284477 DOI: 10.21037/jgo.2015.10.04] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
253 Chen YX, Zhuang Y, Yang P, Fan J, Zhou J, Hu Y, Zhu WC, Sun J, Zeng ZC. Helical IMRT-Based Stereotactic Body Radiation Therapy Using an Abdominal Compression Technique and Modified Fractionation Regimen for Small Hepatocellular Carcinoma. Technol Cancer Res Treat 2020;19:1533033820937002. [PMID: 32613904 DOI: 10.1177/1533033820937002] [Reference Citation Analysis]
254 Keane FK, Hong TS. Role and Future Directions of External Beam Radiotherapy for Primary Liver Cancer. Cancer Control 2017;24:1073274817729242. [PMID: 28975835 DOI: 10.1177/1073274817729242] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
255 Sapir E, Tao Y, Schipper MJ, Bazzi L, Novelli PM, Devlin P, Owen D, Cuneo KC, Lawrence TS, Parikh ND, Feng M. Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2018;100:122-130. [PMID: 29066120 DOI: 10.1016/j.ijrobp.2017.09.001] [Cited by in Crossref: 66] [Cited by in F6Publishing: 50] [Article Influence: 13.2] [Reference Citation Analysis]
256 Voizard N, Cerny M, Assad A, Billiard JS, Olivié D, Perreault P, Kielar A, Do RKG, Yokoo T, Sirlin CB, Tang A. Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review. Insights Imaging 2019;10:121. [PMID: 31853668 DOI: 10.1186/s13244-019-0801-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
257 Tsai CL, Hsu FM, Cheng JC. How to Improve Therapeutic Ratio in Radiotherapy of HCC. Liver Cancer. 2016;5:210-220. [PMID: 27493896 DOI: 10.1159/000367767] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
258 Gerum S, Jensen AD, Roeder F. Stereotactic body radiation therapy in patients with hepatocellular carcinoma: A mini-review. World J Gastrointest Oncol 2019; 11(5): 367-376 [PMID: 31139307 DOI: 10.4251/wjgo.v11.i5.367] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
259 Jiang P, Dunst J. [Stereotactic body radiation therapy is superior to sorafenib in terms of survival in patients with hepatocellular carcinoma]. Strahlenther Onkol 2019;195:188-9. [PMID: 30552450 DOI: 10.1007/s00066-018-1408-x] [Reference Citation Analysis]
260 Tchelebi L, Zaorsky N, Mackley H. Stereotactic Body Radiation Therapy in the Management of Upper GI Malignancies. Biomedicines 2018;6:E7. [PMID: 29301352 DOI: 10.3390/biomedicines6010007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
261 Velec M, Moseley JL, Dawson LA, Brock KK. Dose escalated liver stereotactic body radiation therapy at the mean respiratory position. Int J Radiat Oncol Biol Phys 2014;89:1121-8. [PMID: 25035217 DOI: 10.1016/j.ijrobp.2014.04.051] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
262 Dehne S, Fritz C, Rieken S, Baris D, Brons S, Haberer T, Debus J, Weber KJ, Schmid TE, Combs SE, Habermehl D. Combination of Photon and Carbon Ion Irradiation with Targeted Therapy Substances Temsirolimus and Gemcitabine in Hepatocellular Carcinoma Cell Lines. Front Oncol 2017;7:35. [PMID: 28348976 DOI: 10.3389/fonc.2017.00035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
263 Li M, Zhao Y, Liu X, Dang Z, Wang X, Jiang Y, Yang Z. Association and interaction between model for end-stage liver disease score and minimally invasive treatment with regard to mortality of patients with hepatitis B virus-associated hepatocellular carcinoma and portal vein tumor thrombi. Oncol Lett 2019;17:119-26. [PMID: 30655746 DOI: 10.3892/ol.2018.9590] [Reference Citation Analysis]
264 Cantaloube M, Castan F, Creoff M, Prunaretty J, Bordeau K, Michalet M, Assenat E, Guiu B, Pageaux GP, Ychou M, Aillères N, Fenoglietto P, Azria D, Riou O. Image-Guided Liver Stereotactic Body Radiotherapy Using VMAT and Real-Time Adaptive Tumor Gating: Evaluation of the Efficacy and Toxicity for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4853. [PMID: 34638336 DOI: 10.3390/cancers13194853] [Reference Citation Analysis]
265 Koay EJ, Owen D, Das P. Radiation-Induced Liver Disease and Modern Radiotherapy. Semin Radiat Oncol 2018;28:321-31. [PMID: 30309642 DOI: 10.1016/j.semradonc.2018.06.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
266 Park SH, Won HJ, Kim SY, Shin YM, Kim PN, Yoon SM, Park JH, Kim JH. Efficacy and safety of ultrasound-guided implantation of fiducial markers in the liver for stereotactic body radiation therapy. PLoS One 2017;12:e0179676. [PMID: 28636658 DOI: 10.1371/journal.pone.0179676] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
267 Chen CP. Role of Radiotherapy in the Treatment of Hepatocellular Carcinoma. J Clin Transl Hepatol. 2019;7:183-190. [PMID: 31293919 DOI: 10.14218/jcth.2018.00060] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]